Clinical trial
N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell…
NCT00005978 · New Approaches to Neuroblastoma Therapy Consortium, Other · Completed
Key facts
| NCT number | NCT00005978 |
|---|---|
| Title | N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With Neuroblastoma |
| Official title | Dose Escalation Study of 131 I-Metaiodobenzylguanidine (MIBG) With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma - A Phase I Study |
| Lead sponsor | New Approaches to Neuroblastoma Therapy Consortium, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neuroblastoma |
| Intervention type | Biological, Drug, Procedure, Radiation |
| Interventions | filgrastim, carboplatin, etoposide, melphalan, autologous bone marrow transplantation, peripheral blood stem cell transplantation, iobenguane I 131, radiation therapy |
| Start date | May 1, 2000 |
| Primary completion | Dec 1, 2004 |
| First posted | Dec 23, 2003 |
| Last update posted | Oct 15, 2010 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: